Lineage Cell Therapeutics Inc (LCTX)

[terry hallinan]

BioTime Further Expands OpRegen(R) Clinical Trial in Dry-AMD With the Opening of Two Additional U.S. Sites

Diana V. Do, MD, Professor of Ophthalmology at the Byers Eye Institute, Stanford University School of Medicine
David Telander, MD, PhD at The Retinal Consultants Medical Group serving northern California

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced the expansion of its ongoing Phase I/IIa clinical trial for OpRegen®, with the addition of two new U.S. sites that are expected to begin treating patients later this quarter.

“The addition of these two leading U.S. clinical trial sites is in addition to our current two sites in California. We are actively recruiting patients and are in line with our plans to meet our patient enrollment projections over the next few months,” commented Dr. Gary S. Hogge, Senior Vice President of Clinical and Medical Affairs of BioTime.

To speed up enrollment?? It doesn't say and likely means it is just in line with initial plans.

It pleases me to think this is a very big deal with BTX all alone in treating dry AMD.

JMO as always.

Best, Terry